TVTX (Travere Therapeutics) Effective Interest Rate on Debt %: 1.81% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TVTX Travere Therapeutics Inc TVTX
61 GF Score
Price $65.71
GF Value $36.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Travere Therapeutics Effective Interest Rate on Debt %?

Travere Therapeutics TVTX +1.96% 61 Effective Interest Rate on Debt % is 1.81% as of Jun. 2026. GuruFocus rates TVTX with a GF Score™ of 61/100 and a GF Value™ of $36.75 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Travere Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Jun. 2026 was $8.5 Mil. Travere Therapeutics's average total debt for the quarter that ended in Jun. 2026 was $472.3 Mil. Therefore, Travere Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2026 was 1.81%.


Travere Therapeutics  (NAS:TVTX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Travere Therapeutics Effective Interest Rate on Debt % Related Terms


Travere Therapeutics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Travere Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Travere Therapeutics Effective Interest Rate on Debt % Chart

Travere Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.78 3.29 2.79 2.77 2.94

Travere Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 3.02 2.79 2.80 1.81

TVTX vs ORKA, DNTH, SRRK: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Travere Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Travere Therapeutics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Effective Interest Rate on Debt % falls into.


TVTX
61GF Score
Travere Therapeutics Inc TVTX
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Travere Therapeutics Effective Interest Rate on Debt % Calculation

Travere Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  -10.748/( (401.584+328.733)/ 2 )
=-1  *  -10.748/365.1585
=2.94 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=327.501 + 74.083
=401.584

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=322.858 + 5.875
=328.733

Travere Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Mar. 2026 )+Total Debt  (Q: Jun. 2026 ))/ count )
=-1  *  -8.536/( (327.662+616.905)/ 2 )
=-1  *  -8.536/472.2835
=1.81 %

where

Total Debt  (Q: Mar. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=321.645 + 6.017
=327.662

Total Debt  (Q: Jun. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=610.742 + 6.163
=616.905

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jun. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 1.81% mean?
Travere Therapeutics (TVTX) has a Effective Interest Rate on Debt % of 1.81% as of Jun. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Travere Therapeutics and its competitors.
Is Travere Therapeutics' Effective Interest Rate on Debt % too high?
Travere Therapeutics' current Effective Interest Rate on Debt % is 1.81%. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Effective Interest Rate on Debt % compare to ORKA and DNTH?
Travere Therapeutics' Effective Interest Rate on Debt % of 1.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Travere Therapeutics and its competitors. Travere Therapeutics's current Effective Interest Rate on Debt % is 1.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Effective Interest Rate on Debt % is 1.81%. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Effective Interest Rate on Debt % is 1.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Travere Therapeutics (TVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued. The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75. GuruFocus considers Travere Therapeutics to be Significantly Overvalued.

Key valuation signals for TVTX:

  • Effective Interest Rate on Debt %: 1.81%
  • GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Travere Therapeutics Business Description

Address 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score

Get the complete analysis for TVTX

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.71
Price
$36.75
GF Value